Ascendis Pharma Posts €213.6M Q3 Revenue, Holds €539M Cash, PDUFA Feb. 28
Ascendis Pharma reported Q3 revenues of €213.6 million, nearly quadrupling year-ago levels, achieving operating profitability and holding €539 million cash. Analyst consensus price target climbed from $270.50 to $307.33 over the past year, and a PDUFA decision for TransCon CNP on February 28 could unlock a multi-billion-euro market.
1. Q3 Financial Results
Ascendis Pharma reported Q3 revenues of €213.6 million, nearly four times year-earlier levels, driven by products Yorvipath and Skytrofa. The company achieved operating profitability for the quarter.
2. Cash Position and Balance Sheet
The company held €539 million in cash, supporting its self-sustaining model and reducing near-term dilution risk.
3. Analyst Sentiment and Price Targets
Analyst consensus price target rose from $270.50 to $307.33 over the past year, reflecting growing optimism, while Bank of America Securities set a $161 target, indicating caution.
4. TransCon CNP FDA Decision
TransCon CNP faces a February 28 PDUFA decision; approval could open a multi-billion-euro market opportunity and drive future growth.